Respiratorius AB
The answer first
Does Respiratorius beat the market?
No, Respiratorius has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 34% of Nordic stocks
- Quality89
- Value24
- Trend17
No. 95 of 195 in healthcare
Max for seven days
Follow Respiratorius with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Respiratorius
Your first answer is free, no account needed.
Do you own Respiratorius, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Respiratorius and a few more. Free, no card.
Super Stock+44.6%In short
- Respiratorius has fallen 32.2% over the past year, including dividends.
- Overall, Respiratorius ranks better than 34% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 97.6%. The price is 99.5% below its peak now.
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 34% of Nordic stocks.
No. 95 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 38 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity–
- Asset turnoverSales divided by everything the company owns0.00
- Return on equityProfit divided by equity−24.3%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 85 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity0.4
- P/SPrice divided by sales957.0
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 135 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−41.8%
- 6 months−38.2%
- 9 months−4.7%
- 12 months−32.2%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
About Respiratorius
Respiratorius AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK.
Respiratorius AB (publ), a research company, develops pharmaceuticals for the treatment of cancer. Its products under development include VAL001, that is in Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma. The company was incorporated in 1998 and is based in Lund, Sweden.


See the full analysis of Respiratorius.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card